vs
Side-by-side financial comparison of A2Z CUST2MATE SOLUTIONS CORP. (AZ) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
A2Z CUST2MATE SOLUTIONS CORP. is the larger business by last-quarter revenue ($1.5M vs $1.4M, roughly 1.1× PLUS THERAPEUTICS, INC.). A2Z CUST2MATE SOLUTIONS CORP. runs the higher net margin — -90.4% vs -417.9%, a 327.5% gap on every dollar of revenue. On growth, A2Z CUST2MATE SOLUTIONS CORP. posted the faster year-over-year revenue change (-1.6% vs -3.2%).
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
AZ vs PSTV — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5M | $1.4M |
| Net Profit | $-1.4M | $-5.7M |
| Gross Margin | 34.0% | — |
| Operating Margin | -265.9% | -420.0% |
| Net Margin | -90.4% | -417.9% |
| Revenue YoY | -1.6% | -3.2% |
| Net Profit YoY | 60.4% | -46.4% |
| EPS (diluted) | — | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.4M | ||
| Q3 25 | $1.5M | $1.4M | ||
| Q2 25 | $1.2M | $1.4M | ||
| Q1 25 | $2.0M | $1.1M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $1.6M | $1.5M | ||
| Q2 24 | $1.1M | $1.3M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | — | $-5.7M | ||
| Q3 25 | $-1.4M | $-4.4M | ||
| Q2 25 | $-12.6M | $5.2M | ||
| Q1 25 | $-6.8M | $-17.4M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | $-3.5M | $-2.9M | ||
| Q2 24 | $-3.2M | $-2.9M | ||
| Q1 24 | — | $-3.3M |
| Q4 25 | — | — | ||
| Q3 25 | 34.0% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 31.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 43.9% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -420.0% | ||
| Q3 25 | -265.9% | -320.8% | ||
| Q2 25 | -585.9% | -110.6% | ||
| Q1 25 | -381.4% | -333.9% | ||
| Q4 24 | — | -276.2% | ||
| Q3 24 | -167.0% | -260.9% | ||
| Q2 24 | -272.1% | -289.1% | ||
| Q1 24 | — | -196.7% |
| Q4 25 | — | -417.9% | ||
| Q3 25 | -90.4% | -316.6% | ||
| Q2 25 | -1085.4% | 370.6% | ||
| Q1 25 | -342.1% | -1643.2% | ||
| Q4 24 | — | -276.4% | ||
| Q3 24 | -224.7% | -197.4% | ||
| Q2 24 | -277.4% | -229.9% | ||
| Q1 24 | — | -194.5% |
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $-0.04 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | $-0.19 | $-1.19 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | $-0.15 | $-0.37 | ||
| Q2 24 | $-0.05 | $-0.71 | ||
| Q1 24 | — | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.2M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $71.3M | $4.0M |
| Total Assets | $81.9M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.6M | ||
| Q3 25 | $43.2M | $16.6M | ||
| Q2 25 | $28.5M | $6.9M | ||
| Q1 25 | $24.2M | $9.9M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $3.4M | $4.8M | ||
| Q2 24 | $653.0K | $8.4M | ||
| Q1 24 | — | $3.2M |
| Q4 25 | — | $4.0M | ||
| Q3 25 | $71.3M | $5.1M | ||
| Q2 25 | $31.5M | $3.0M | ||
| Q1 25 | $31.3M | $-23.6M | ||
| Q4 24 | — | $-8.9M | ||
| Q3 24 | $-504.0K | $-5.2M | ||
| Q2 24 | $-340.0K | $-7.6M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | $81.9M | $18.7M | ||
| Q2 25 | $46.1M | $10.3M | ||
| Q1 25 | $42.2M | $12.1M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | $10.2M | $7.0M | ||
| Q2 24 | $7.2M | $11.2M | ||
| Q1 24 | — | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.0M | $-6.3M |
| Free Cash FlowOCF − Capex | — | $-6.3M |
| FCF MarginFCF / Revenue | — | -459.9% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.3M | ||
| Q3 25 | $-4.0M | $-2.5M | ||
| Q2 25 | $-5.9M | $-5.8M | ||
| Q1 25 | $-3.8M | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-658.0K | $-3.7M | ||
| Q2 24 | $-3.7M | $-1.1M | ||
| Q1 24 | — | $-4.5M |
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | -459.9% | ||
| Q3 25 | — | -184.3% | ||
| Q2 25 | — | -417.6% | ||
| Q1 25 | — | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | — | -253.7% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -271.5% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
